Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY 3670549 · 1 trial · 1 indication
AF = atrial fibrillation ; SR = sinus rhythm ; SoC = Standard of Care;
| Arm | Type | Description |
|---|---|---|
| BAY 3670549 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BAY 3670549 | DRUG | intravenous (IV) treatment |
| Placebo | OTHER | intravenous (IV) treatment |
Inclusion Criteria: * Participant must be 18 to 85 years of age inclusive, at the time of signing the informed consent. * Participant is hemodynamically stable and does not require emergency cardioversion, as determined by the investigator. * Participant has a current episode of atrial fibrillation...
BAY 3670549 is an investigational small molecule being developed for the treatment of atrial fibrillation, a cardiovascular condition characterized by an irregular and often rapid heart rate. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
The specific molecular target of BAY 3670549 has not been disclosed in available information. It is a small molecule being studied for its efficacy and safety in patients with atrial fibrillation, but its mechanism of action is not publicly detailed.
BAY 3670549 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY.
BAY 3670549 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies and is still undergoing clinical trials to evaluate its safety and effectiveness.
BAY 3670549 is being studied in a Phase 2 clinical trial with the identifier NCT07625215. This randomized, double-blind, placebo-controlled study is designed to evaluate the drug's efficacy and safety in approximately 360 patients with atrial fibrillation. The trial is not yet recruiting participants.